Webinar: Quantitative imaging for dementia

July 27, 2021

Product: NeuroQuant
Disease: Alzheimer's disease, Neurodementias

This is the first in a series of case reviews using quantitative imaging in the assessment of various neurological diseases. Dr. Bash, neuroradiologist at RadNet, uses NeuroQuant and other tools in her review of seven dementia patient cases.

Visit the NeuroQuant Dementia page to learn more.

LENGTH

Approximately 7 Minutes

PRESENTED BY

Dr. Suzie Bash, Neuroradiologist at RadNet

WHO SHOULD WATCH?

Neurologists
Neuroradiologists
Researchers
Neuroscientists
Primary Care Physicians
Nurses

Want to see more?

10/20/2026

NeuroQuant PET Explained

Discover how NeuroQuant PET helps radiologists and neurologists move beyond visual reads.

10/13/2026

NeuroQuant PET Is Now FDA Cleared

NeuroQuant PET is now FDA cleared, with centiloid estimation for amyloid PET and support for all FDA-approved dementia tracers.

10/13/2026

Know Where Your Patient Started: Centiloids in the Era of Anti-Amyloid Therapy

Neuroradiologist Dr. Suzie Bash explains why baseline centiloid values from amyloid PET are key to anti-amyloid maintenance dosing decisions.

10/01/2026

Comprehensive Insights on Metastatic Melanoma with NeuroQuant® CT | Dr. Niky Farid

By bringing key imaging findings together into a single structured report, NeuroQuant CT helps radiologists and clinicians quickly review critical information.

10/01/2026

Transforming Prostate Cancer Care with OnQ™ Prostate

OnQ Prostate adds color-coded imaging insights that help clinicians more clearly visualize regions.

10/01/2026

Why OnQ Prostate Is Different from Other Prostate Imaging Technologies

Learn how OnQ Prostate differs from other prostate imaging technologies and how its advanced diffusion modeling can provide clearer visualization.

Our solutions

Our solutions

About

Support

Resources